Want to see IN:SENORES full AI Analyst Report?
Senores Pharmaceuticals Ltd. (SENORES) Ratios
Senores Pharmaceuticals Ltd. Ratios
IN:SENORES's free cash flow for Q2 2025 was $-724.70M. For the 2025 fiscal year, IN:SENORES's free cash flow was decreased by $-966.90M and operating cash flow was $242.20M. See a summary of the company’s cash flow.
| Ratios | Mar 25 | Mar 25 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 3.00 | 1.92 |
| Quick Ratio | 2.77 | 1.71 |
| Cash Ratio | 0.44 | 0.11 |
| Solvency Ratio | 3.46 | 0.23 |
| Operating Cash Flow Ratio | -0.19 | 0.15 |
| Short-Term Operating Cash Flow Coverage | -0.32 | 0.47 |
| Net Current Asset Value | $ 7.17B | $ 1.73B |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 21.61 | 0.21 |
| Debt-to-Equity Ratio | 0.40 | 0.37 |
| Debt-to-Capital Ratio | 0.29 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.17 | 0.17 |
| Financial Leverage Ratio | 0.02 | 1.72 |
| Debt Service Coverage Ratio | 0.66 | 1.13 |
| Interest Coverage Ratio | 3.57 | 5.48 |
| Debt to Market Cap | 0.15 | 0.10 |
| Interest Debt Per Share | 92.15 | 83.95 |
| Net Debt to EBITDA | 1.94 | 1.38 |
| Profitability Margins | ||
| Gross Profit Margin | 0.37% | 60.22% |
| EBIT Margin | 23.76% | 29.11% |
| EBITDA Margin | 28.16% | 34.05% |
| Operating Profit Margin | 19.02% | 21.67% |
| Pretax Profit Margin | 18.44% | 25.15% |
| Net Profit Margin | 0.18% | 18.24% |
| Continuous Operations Profit Margin | 0.18% | 19.21% |
| Net Income Per EBT | 0.97% | 72.52% |
| EBT Per EBIT | 96.92% | 116.07% |
| Return on Assets (ROA) | 4.70% | 7.19% |
| Return on Equity (ROE) | 0.09% | 12.36% |
| Return on Capital Employed (ROCE) | -32.20% | 11.62% |
| Return on Invested Capital (ROIC) | 11.50% | 7.97% |
| Return on Tangible Assets | -0.33% | 9.47% |
| Earnings Yield | 0.03% | 3.41% |
| Efficiency Ratios | ||
| Receivables Turnover | 1.58 | 1.95 |
| Payables Turnover | 4.11 | 1.07 |
| Inventory Turnover | 0.06 | 2.82 |
| Fixed Asset Turnover | 1.47 | 1.74 |
| Asset Turnover | 26.28 | 0.39 |
| Working Capital Turnover Ratio | 0.00 | 1.45 |
| Cash Conversion Cycle | 6533.90 | -23.52 |
| Days of Sales Outstanding | 230.63 | 187.41 |
| Days of Inventory Outstanding | 6391.97 | 129.50 |
| Days of Payables Outstanding | 88.70 | 340.43 |
| Operating Cycle | 6622.60 | 316.91 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | -12.63 | 14.19 |
| Free Cash Flow Per Share | -55.94 | -46.36 |
| Dividend Paid and CapEx Coverage Ratio | -0.29 | 0.23 |
| Capital Expenditure Coverage Ratio | -0.29 | 0.23 |
| Operating Cash Flow Coverage Ratio | -0.15 | 0.18 |
| Operating Cash Flow to Sales Ratio | -0.12 | 0.10 |
| Free Cash Flow Yield | -9.92% | -5.98% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | 2968.16 | 29.36 |
| Price-to-Sales (P/S) Ratio | 5.36 | 5.35 |
| Price-to-Book (P/B) Ratio | 2.61 | 3.63 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -10.08 | -16.71 |
| Price-to-Operating Cash Flow Ratio | -44.66 | 54.59 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 |
| Enterprise Value Multiple | 20.97 | 17.10 |
| Enterprise Value | 22.60B | 36.84B |
| EV to EBITDA | 20.97 | 17.10 |
| EV to Sales | 5.90 | 5.82 |
| EV to Free Cash Flow | -11.11 | -18.18 |
| EV to Operating Cash Flow | -49.22 | 59.37 |
| Tangible Book Value Per Share | -58.10 | 132.48 |
| Shareholders’ Equity Per Share | 216.18 | 213.54 |
| Tax and Other Ratios | ||
| Effective Tax Rate | 0.00 | 0.24 |
| Revenue Per Share | 105.26 | 144.70 |
| Net Income Per Share | 0.19 | 26.39 |
| Tax Burden | 0.01 | 0.73 |
| Interest Burden | 0.78 | 0.86 |
| Research & Development to Revenue | 0.01 | 0.00 |
| SG&A to Revenue | 0.04 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 |
| Income Quality | -0.65 | 0.39 |
Currency in INR